Top Markets
Coin of the day
Becton, Dickinson and Company Becton, Dickinson and Company

Becton, Dickinson and Company

BDX
Rank in Stocks #492
Operating globally, Becton, Dickinson and Company (BD) is a prominent... Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Share Price
$183.43
Market Cap
$50.54B
Change (1 day)
2.13%
Change (1 year)
29.20%
Country
US
Trade Becton, Dickinson and Company (BDX)

Category

P/E ratio for Becton, Dickinson and Company (BDX)
P/E ratio as of September 2026 TTM: 55.09
According to Becton, Dickinson and Company latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 55.09. At the end of 2024 the company had a P/E ratio of 40.97.
P/E ratio history for Becton, Dickinson and Company from 2000 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) 55.09 72.33%
2025 31.97 -21.98%
2024 40.97 -17.84%
2023 49.87 39.71%
2022 35.70 7.72%
2021 33.14 -54.23%
2020 72.41 34.11%
2019 53.99 -74.78%
2018 214.12 463.11%
2017 38.02 -0.43%
2016 38.19 1.32%
2015 37.69 108.24%
2014 18.10 22.98%
2013 14.72 8.89%
2012 13.52 8.66%
2011 12.44 -3.18%
2010 12.85 -3.24%
2009 13.28 -21.73%
2008 16.96 -23.68%
2007 22.23 -1.92%
2006 22.66 27.31%
2005 17.80 -34.36%
2004 27.12 65.54%
2003 16.38 10.04%
2002 14.89 -35.06%
2001 22.93 38.04%
2000 16.61 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
42.71 -22.49%
US
27.35 -50.35%
FR
- -
JP
- -
CH
- -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.